简介
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
总部
San Francisco, California, USA
成立于
2013
类型
实验室
生态系统
1
法律身份
- 法定名称
- Calico Life Sciences LLC
- 状态
- 活跃
- 核验日期
- 2026-08-30
- 下次复核
- 2026-11-30
使命
“Harness advanced technologies to increase human healthspan.”
重点领域
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
战略路线图
2025 Q4
● 进行中ABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
长寿与抗衰老
2026 Q4
◯ 已规划Combination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
长寿与抗衰老
2028 Q2
◯ 已规划Age reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
长寿与抗衰老